medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2023, Number 1

<< Back Next >>

Rev Mex Urol 2023; 83 (1)

Functional outcomes and complications following transurethral surgical procedures for the treatment of benign prostatic obstruction

Alarcón-Salvador JF

Language: Spanish
References: 22
Page:
PDF size: 295.98 Kb.


ABSTRACT

Introduction: Benign prostatic hyperplasia is a disease that affects men variably over time, affecting their lifestyle with irritative and obstructive urinary symptoms. One treatment option is transurethral resection of the prostate. However, there are currently new, innovative and advantageous transurethral techniques. The aim of this review is to contribute to current knowledge of the different functional outcomes and complications of the main transurethral techniques.
Methods. A literature review was conducted between December 2021 and January 2022 in the PubMed and Cochrane databases. The quality of the articles was assessed by applying PRISMA 2020 and AGREE on II recommendations.
Results. A total of four articles were selected for the final paper. It was determined that there is currently no standard technique for the treatment of benign prostatic hyperplasia; laser enucleation techniques (HoLEP) are a safe option in anticoagulated patients and can be used regardless of prostate size.
Conclusions. The present review highlights the literature gaps regarding the selection of a standard transurethral surgical technique for the treatment of obstructive symptoms secondary to benign prostatic hyperplasia. The use of various types of lasers is recommended in view of improved functional outcomes; M-RTUP is associated with more post-surgical bleeding relative to other techniques. Long-term randomized controlled trials with a larger number of comparisons are needed to outline the best technique. However, the treatment of patients with benign prostatic hyperplasia should be highly individualized.


REFERENCES

  1. Robles-Rodríguez A, Garibay-Huarte TR,Acosta-Arreguín E, Morales-López S. Lapróstata: generalidades y patologías másfrecuentes. Revista de la Facultad de MedicinaUNAM. 2019;62(4): 41–54.

  2. Elshal A, Soltan M, El-Tabey N, Laymon M,Nabeeh H, Nabeeh A. 121 - Challenging largesized benign prostate hyperplasia throughrandomized trial of bipolar resection vs. holmiumlaser enucleation vs. Green Light laser vapoenucleationof the prostate. European UrologySupplements. 2018;17(2): e177–e179. https://doi.org/10.1016/S1569-9056(18)30973-4.

  3. Hernández MB. Hiperplasia prostática benigna.Revista Medica Sinergia. 2017;2(8): 11–16.https://revistamedicasinergia.com/index.php/rms/article/view/91

  4. Almeida FG, Silva LT. BPH treatment: laserfor everyone | Opinion: NO. InternationalBrazilian Journal of Urology: official journal of theBrazilian Society of Urology. 2018;44(2): 215–218. https://doi.org/10.1590%2FS1677-5538.IBJU.2018.02.03.

  5. Gravas S, Cornu JN, Gacci M, Gratzke C,Herrmann TRW, Mamoulakis C, et al. EAUGuidelines on the Management of Non-neurogenicMale LUTS , incl. Bening Prostatic Obstruction(BPO). Netherlands: European Association ofUrology; 2022. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts[Accessed 23rd February 2023].

  6. Lerner LB, McVary KT, Barry MJ, Bixler BR,Dahm P, Das AK, et al. Management of LowerUrinary Tract Symptoms Attributed to BenignProstatic Hyperplasia: AUA GUIDELINEPART I—Initial Work-up and MedicalManagement. Journal of Urology. 2021;206(4):806–817. https://doi.org/10.1097/JU.0000000000002183.

  7. Zheng X, Han X, Cao D, Wang Y, Xu H,Yang L, et al. Comparison of Short-TermOutcomes between Button-Type Bipolar PlasmaVaporization and Transurethral Resectionfor the Prostate: A Systematic Review andMeta-Analysis. International Journal of MedicalSciences. 2019;16(12): 1564–1572. https://doi.org/10.7150%2Fijms.38618.

  8. Wang YB, Yan SY, Xu XF, Huang X, Luo LS,Deng YQ, et al. Comparison on the Efficacyand Safety of Different Surgical Treatments forBenign Prostatic Hyperplasia With Volume >60mL: A Systematic Review and Bayesian NetworkMeta-Analysis of Randomized ControlledTrials. American Journal of Men’s Health.2021;15(6): 15579883211067086. https://doi.org/10.1177/15579883211067086.

  9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I,Hoffmann TC, Mulrow CD, et al. DeclaraciónPRISMA 2020: una guía actualizada parala publicación de revisiones sistemáticas.Revista Española de Cardiología. 2021;74(9):790–799. https://www.revespcardiol.org/es-declaracion-prisma-2020-una-guiaarticulo-S0300893221002748.

  10. AGREE-HS Research Team. Appraisal ofGuidelines Research & Evaluation—HealthSystems: AGREE-HS. AGREE-HS ResearchTeam; 2018.

  11. Sousa M, Navas Z, Laborde M, José J, CarrascosaU. Niveles de Evidencia Clínica y Grados deRecomendación. Revista de la Sociedad Andaluzade Traumatología y Ortopedia. 2012;29(1):59–72. https://www.repositoriosalud.es/bitstream/10668/1568/6/Mella_Niveles.pdf

  12. Huang SW, Tsai CY, Tseng CS, Shih MC, YehYC, Chien KL, et al. Comparative efficacy andsafety of new surgical treatments for benignprostatic hyperplasia: systematic review andnetwork meta-analysis. BMJ (Clinical researched.). 2019;367: l5919. https://doi.org/10.1136/bmj.l5919.

  13. Sun F, Sun X, Shi Q, Zhai Y. Transurethralprocedures in the treatment of benign prostatichyperplasia: A systematic review and meta-analysis of effectiveness and complications.Medicine. 2018;97(51): e13360. https://doi.org/10.1097/md.0000000000013360.

  14. Parsons JK, Dahm P, Köhler TS, Lerner LB,Wilt TJ. Surgical Management of Lower UrinaryTract Symptoms Attributed to Benign ProstaticHyperplasia: AUA Guideline Amendment 2020.The Journal of Urology. 2020;204(4): 799–804. https://doi.org/10.1097/ju.0000000000001298.

  15. Homma Y, Gotoh M, Kawauchi A, Kojima Y,Masumori N, Nagai A, et al. Clinical guidelinesfor male lower urinary tract symptoms and benignprostatic hyperplasia. International Journalof Urology: Official Journal of the Japanese UrologicalAssociation. 2017;24(10): 716–729. https://doi.org/10.1111/iju.13401.

  16. Anan G, Kaiho Y, Iwamura H, Ito J, Kohada Y,Mikami J, et al. Preoperative pelvic floor muscleexercise for early continence after holmiumlaser enucleation of the prostate: a randomizedcontrolled study. BMC Urology. 2020;20: 3. https://doi.org/10.1186%2Fs12894-019-0570-5.

  17. Leonardo C, Lombardo R, Cindolo L, AntonelliA, Greco F, Porreca A, et al. What is thestandard surgical approach to large volumeBPE? Systematic review of existing randomizedclinical trials. Minerva Urologica e Nefrologica.2020;72(1). https://doi.org/10.23736/S0393-2249.19.03589-6.

  18. Elshal AM, Soltan M, El-Tabey NA, Laymon M,Nabeeh A. Randomised trial of bipolar resectionvs holmium laser enucleation vs Greenlight laservapo-enucleation of the prostate for treatmentof large benign prostate obstruction: 3-yearsoutcomes. BJU international. 2020;126(6):731–738. https://doi.org/10.1111/bju.15161.

  19. Teng TC, Shao IH, Hsu YC, Chen Y, Tsao SH,Kang YT, et al. Risk Factors of EmergencyRoom Visits for Bleeding Complications FollowingTransurethral Procedures in the Treatmentof Benign Prostatic Hyperplasia: A RetrospectiveCohort Study. Clinical Interventionsin Aging. 2021;16: 1747–1756. https://doi.org/10.2147%2FCIA.S329468.

  20. Rivera M, Krambeck A, Lingeman J. HolmiumLaser Enucleation of the Prostate in Patients RequiringAnticoagulation. Current Urology Reports.2017;18(10): 77. https://doi.org/10.1007/s11934-017-0727-2.

  21. Davies B. Responsibility and the limits of patientchoice. Bioethics. 2020;34(5): 459–466.https://doi.org/10.1111/bioe.12693.

  22. Akan S, Ediz C, Özer E, Pehlivanoğlu M, TavukçuHH, Kıymaz K, et al. Efficacy and Safetyof Monopolar Transurethral Resection of theProstate on Bleeding Control in the Treatmentof Benign Prostatic Obstruction: Is It Still a GoodOption in Developing Countries? The Bulletin ofUrooncology. 2020;19(3): 157–161. http://dx.doi.org/10.4274/uob.galenos.2020.1655.




2020     |     www.medigraphic.com